Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments

Journal of Virology

Volumn 72, Issue 7, 1998, Pages 5927-5936

  Cihlar, Tomas ^a   Fuller, Michael D ^a   Cherrington, Julie M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DNA FRAGMENT; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; LOBUCAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS RECOMBINANT;

EID: 0031775862     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.7.5927-5936.1998     Document Type: Article

References (58)

1. Anders, D. G., M. A. Kacica, G. Pari, and S. M. Punturieri. 1992. Boundaries and structure of human cytomegalovirus orilyt, a complex origin for lytic-phase DNA replication. J. Virol. 66:3373-3384.
2. Baldanti, F., A. Sarasini, E. Silini, M. Barbi, A. Lazzarin, K. K. Biron, and G. Gerna. 1995. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir-and foscarnet-specific resistance, respectively. Scand. J. Infect. Dis. Supl. 99:103-104.
3. Baldanti, F., E. Silini, A. Sarasini, C. L. Talarico, S. C. Stanat, K. K. Biron, M. Furione, F. Bono, G. Palu, and G. Gerna. 1995. A three-nucleotide deletion in the UL97 open reading frame is responsible for the gancictovir resistance of a human cytomegalovirus clinical isolate. J. Virol. 69:796-800.
4. Baldanti, F., M. R. Underwood, S. C. Stanat, K. K. Biron, S. Chou, A. Sarasini, E. Silini, and G. Gerna. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1390-1395.
5. Bernad, A., L. Blanco, J. M. Lazaro, G. Martin, and M. Salas. 1989. A conserved 3′-5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell 59:219-228.
6. Biron, K. K., and F. Baldanti. 1996. Nucleosides and foscarnet - mechanisms, p. 125-152. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley & Sons Ltd., New York, N.Y.
7. Blanco, L., A. Bernad, M. A. Blasco, and M. Salas. 1991. A general structure for DNA-dependent DNA polymerases. Gene 100:27-38.
8. Cherrington, J. M., et al. 1997. Unpublished data.
9. Cherrington, J. M., M. D. Fuller, P. D. Lamy, R. Miner, J. P. Lalezari, S. Nuessle, and W. L. Drew. In vitro antiviral susceptibilities of isolates from CMV retinitis patients receiving first or second line cidofovir therapy: relationship to clinical outcome. Submitted for publication.
10. Cherrington, J. M., R. Miner, M. J. M. Hitchcock, J. P. Lalezari, and W. L. Drew. 1996. Susceptibility of human cytomegalovirus (HCMV) to cidofovir is unchanged after limited in vivo exposure to various clinical regimens of drug. J. Infect. Dis. 173:987-992.
11. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michel, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
12. Chou, S., G. Marousek, D. Parenti, J. Lalezari, R. Miner, and L. Drew. 1997. Mutation in region III of the DNA polymerase gene associated with dual ganciclovir-foscarnet resistance in cytomegalovirus (CMV) isolates from three subjects receiving prolonged antiviral therapy, abstr. 510, p. 166. In Abstracts from the 35th Annual Meeting of Infectious Diseases Society of America.
13. Chou, S., G. Marousek, S. Guentzel, S. E. Follansbee, M. E. Poscher, J. P. Lalezari, R. C. Miner, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalo-virus disease. J. Infect. Dis. 176:786-789.
14. Chrisp, P., and S. P. Clissold. 1991. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
15. Cihlar, T., and M. S. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510.
16. Cihlar, T., M. D. Fuller, and J. M. Cberrington. 1997. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/transplantation system. Protein Exp. Purif. 11:209-218.
17. Coen, D. M. 1996. Viral DNA polymerases, p. 495-523. In M. L. DePamphilis (ed.), DNA replication in eucaryotic cells. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
18. Coen, D. M. 1996. Nucleosides and foscarnet - mechanisms, p. 81-102. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley & Sons Ltd., New York, N.Y.
19. Crumpacker, C. S. 1996. Ganciclovir. Drug Therapy 335:721-729.
20. Derse, D., K. F. Bastow, and Y-C. Cheng. 1982. Characterization of the DNA polymerases induced by a group of herpes simplex virus type 1 variants selected for growth in the presence of phosphonoformic acid. J. Biol. Chem. 257:10251-10260.
21. Erice, A., C. Gil-Roda, J. Pérez, H. H. Balfour Jr., K. J. Sannerud, M. N. Hanson, G. Boivin, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092.
22. Erice, A., S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, and M. C. Jordan. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293.
23. Field, A. K., and K. K. Biron. 1994. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7:1-13.
24. Foster, S. A., J. Cerny, and Y.-C. Cheng. 1991. Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. J. Biol. Chem. 266:238-244.
25. Gibbs, J. S., H. C. Chiou, K. F. Bastow, Y-C. Cheng, and D. M. Coen. 1988. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc. Natl. Acad. Sci. USA 85: 6672-6676.
26. Gilguin, J., C. Piketty, V. Thomas, G. Gonzales-Canali, L. Belec, and M. D. Kazatchkine. 1997. Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 cells/ml following combination antiretroviral therapy including protease inhibitors. AIDS 11:1659-1660.
27. Higuchi, R., B. Krummel, and R. K. Saiki. 1988. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 16:7351-7367.
28. Hitchcock, M. J. M., H. S. Jaffe, J. C. Martin, and R. J. Stagg. 1996. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem. Chemother. 7:115-127.
29. Hwang, C. B. C., K. L. Ruffner, and D. M. Coen. 1992. A point mutation within the distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J. Virol. 66:1774-1776.
30. Jacobson, M. A., N. Zegans, P. R. Pavan, J. J. O'Donnell, F. Sattler, S. Owens, and R. Pollard. 1997. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349:1443-1445.
31. Kemble, G., G. Duke, R. Winter, and R. Spaete. 1996. Defined large-scale alternation of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J. Virol. 70:2044-2048.
32. Lalezari, J. P. 1997. Cidofovir: a new therapy for cytomegalovirus retinitis. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 14:S22-S26.
33. Larder, B. A., S. D. Kemp, and G. Darby. 1987. Related functional domains in virus DNA polymerases. EMBO J. 6:169-175.
34. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
35. Littler, E., A. D. Stuart, and M. S. Chee. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
36. Lurain, N. S., K. D. Thompson, E. W. Holmes, and G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:7146-7152.
37. Lurain, N. S., L. E. Spafford, and K. D. Thompson. 1994. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:4427-4431.
38. Mar, E.-C., J.-F. Chiou, Y.-C. Cheng, and E.-S. Huang. 1985. Inhibition of cellular DNA polymerase a and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol. 53:776-780.
39. Öberg, B. 1989. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 40:213-285.
40. Pari, G. S., and D. G. Anders. 1993. Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication. J. Virol. 67:6979-6988.
41. Pari, G. S., M. A. Kacica, and D. G. Anders. 1993. Open reading frames UL44, IRS1/TRS1, and UL36-38 are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA synthesis. J. Virol. 67:2575-2582.
42. Rubin, R. H. 1990. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12:S754-S766.
43. Sarasini, A., F. Baldanti, M. Furione, E. Percivalle, R. Brerra, M. Barbi, and G. Gerna. 1995. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J. Med. Virol. 47:237-244.
44. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
45. Smith, I. L., M. Flores-Aguilar, I. Taskituna, R. E. Jiles, W. R. Freeman, and S. A. Spector. 1996. Cytomegalovirus resistance is associated with clinical failure in AIDS patients receiving ganciclovir treatment for retinitis, abstr. H30, p. 168. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy.
46. Snoeck, R., G. Andrei, and E. De Clercq. 1996. Patterns of resistance and sensitivity to antiviral compounds of drug resistant strains of human cytomegalovirus selected in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 15:574-579.
47. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. 1997. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet and ganciclovir. J. Infect. Dis. 176:50-58.
48. Sullivan, V., and D. M. Coen. 1991. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J. Infect. Dis. 164:781-784.
49. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in cytomegalovirus-infected cells. Nature 358:162-164.
50. Sullivan, V., K. K. Biron, C. L. Talarico, S. C. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
51. Tenney, D. J., G. Yamanaka, S. M. Voss, C. W. Cianci, A. V. Tuomari, A. K. Sheaffer, M. Alam, and R. J. Colonno. 1997. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrob. Agents Chemother. 41:2680-2685.
52. Wang, T. S.-F. 1996. Enzymatic properties and characteristics that distinguish each DNA polymerase, p. 461-493. In M. L. DePamphilis (ed.), DNA replication in eucaryotic cells. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
53. Wolf, D. G., I. L. Smith, D. J. Lee, W. R. Freeman, M. Flores-Aguilar, and S. A. Spector. 1995. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Invest. 95:257-263.
54. Wong, S. W., A. F. Wahl, P.-M. Yuan, N. Arai, B. E. Pearson, K.-I. Arai, D. Korn, M. W. Hunkapiller, and T. S.-F. Wang. 1988. Human DNA polymerase a gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases. EMBO J. 7:37-47.
55. Xiong, X., C. Flores, M. D. Fuller, D. B. Mendel, A. S. Mulato, K. Moon, M. S. Chen, and J. M. Cherrington. 1997. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir). Antiviral Res. 36:131-137.
56. Xiong, X., J. L. Smith, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594-599.
57. Ye, L.-B., and E.-S. Huang. 1993. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J. Virol. 67:6339-6347.
58. Zhang, J., D. W. Chung, C.-K. Tan, K. M. Downey, E. W. Davie, and A. G. So. 1991. Primary structure of the catalytic subunit of calf thymus DNA polymerase δ: sequence similarities with other DNA polymerases. Biochemistry 30:11742-11750.